ArticleJournal of feline medicine and surgery2025
Ultrasonographic characteristics of renal lymphoma in cats receiving chemotherapy.
Article in Journal of feline medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasonographic features of feline renal neoplasia: a retrospective study on 187 cases.Journal of feline medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesThe aim of this study was to describe renal ultrasonographic (US) findings in cats with confirmed renal lymphoma receiving chemotherapy and correlate them with clinical and clinicopathological findings.MethodsFor this multicenter retrospective study, cats were included if they had cyto-/histological confirmation of renal lymphoma, received multiagent chemotherapy, and US images of the kidneys before and after treatment were available. All images at T0 (diagnosis) and T1 (after chemotherapy) were reviewed. Oncology records were reviewed, and serum creatinine and blood urea nitrogen (BUN) concentrations were recorded, when available.ResultsA total of 24 cats (20 males, 4 females; median age 8 years) who underwent vincristine, cyclophosphamide and prednisolone (COP)-based chemotherapy were included. At T1 (median 33 days, range 20-60), 21 cats were considered to have experienced clinical benefit (20 with improved renal appearance on ultrasound, one with static appearance), two cats had stable clinical findings (one stable, one progressive ultrasound) and one cat clinically declined (progressive ultrasound). On ultrasonography, nephromegaly resolved in 12/20 cats, hypoechoic subcapsular rim disappeared in 6/17 and reduced in 7/17, and nodules and/or masses disappeared in 8/14 and reduced in 5/14 cats. Six cats had normal creatinine and BUN concentrations at both T0 and T1 (five improved and one with stable ultrasound findings); in 11 cats, the azotemia detected at T0 resolved at T1; four cats were persistently azotemic (all with reduced creatinine and BUN concentrations) and one cat became azotemic on T1 (progressive ultrasonography).Conclusions and relevanceAfter chemotherapy, kidneys affected by lymphoma commonly returned to their regular size; subcapsular rim, nodules and masses markedly reduced or completely resolved. US findings were often in agreement with clinical and clinicopathological findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.